<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35137229</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1745-1701</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>48</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>07</Day>
            </PubDate>
          </JournalIssue>
          <Title>Schizophrenia bulletin</Title>
          <ISOAbbreviation>Schizophr Bull</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials.</ArticleTitle>
        <Pagination>
          <StartPage>643</StartPage>
          <EndPage>654</EndPage>
          <MedlinePgn>643-654</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1093/schbul/sbac001</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Weight gain is among the most important side-effects of antipsychotics. It is, however, unclear whether it is associated with antipsychotic doses. We aimed to fill this gap with a dose-response meta-analysis.</AbstractText>
          <AbstractText Label="METHODS">We searched multiple electronic databases (last update search June 2021) for all fixed-dose studies that investigated 16 second-generation antipsychotics and haloperidol in adults with acute exacerbation of schizophrenia or with negative symptoms. We estimated the dose-response curves by conducting random-effects dose-response meta-analyses. We used the restricted cubic spline to model the dose-response relationship. The primary outcome was mean weight gain in kg from baseline to endpoint, the secondary outcome was the number of patients with clinically important weight gain.</AbstractText>
          <AbstractText Label="FINDINGS">Ninety-seven studies with 333 dose arms (36 326 participants) provided data for meta-analyses. Most studies were short-term with median duration of 6 weeks (range 4 to 26 weeks). In patients with acute exacerbation, amisulpride, aripiprazole, brexpiprazole, cariprazine, haloperidol, lumateperone, and lurasidone produced mild weight gain in comparison to placebo (mean difference at any dose≤1 kg), while more significant weight gain was observed by all other drugs. For most drugs, dose-response curves showed an initial dose-related increase in weight which plateaued at higher doses, while for others there was no plateau and some even had bell-shaped curves, meaning less weight gain to be associated with higher doses.</AbstractText>
          <AbstractText Label="INTERPRETATION">Second-generation antipsychotics do not only differ in their propensity to produce weight gain, but also in the shapes of their dose-response curves. This information is important for dosing decisions in clinical practice.</AbstractText>
          <CopyrightInformation>© The Author(s) 2022. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Hui</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, Munich, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Siafis</LastName>
            <ForeName>Spyridon</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, Munich, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hamza</LastName>
            <ForeName>Tasnim</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schneider-Thoma</LastName>
            <ForeName>Johannes</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, Munich, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Davis</LastName>
            <ForeName>John M</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>Psychiatric Institute, University of Illinois at Chicago, Chicago, IL, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Maryland Psychiatric Research Center, Baltimore, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Salanti</LastName>
            <ForeName>Georgia</ForeName>
            <Initials>G</Initials>
            <Identifier Source="ORCID">0000-0002-3830-8508</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Leucht</LastName>
            <ForeName>Stefan</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0002-4934-4352</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, Munich, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Psychiatry, Psychology and Neuroscience, Department of Psychiatry, Department of Psychosis Studies, King's College London, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D017418">Meta-Analysis</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Schizophr Bull</MedlineTA>
        <NlmUniqueID>0236760</NlmUniqueID>
        <ISSNLinking>0586-7614</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>J6292F8L3D</RegistryNumber>
          <NameOfSubstance UI="D006220">Haloperidol</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>N7U69T4SZR</RegistryNumber>
          <NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014150" MajorTopicYN="Y">Antipsychotic Agents</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006220" MajorTopicYN="N">Haloperidol</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015430" MajorTopicYN="N">Weight Gain</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">dose-response relationship</Keyword>
        <Keyword MajorTopicYN="Y">metabolic side- effects</Keyword>
        <Keyword MajorTopicYN="Y">olanzapine</Keyword>
        <Keyword MajorTopicYN="Y">paliperidone</Keyword>
        <Keyword MajorTopicYN="Y">quetiapine</Keyword>
        <Keyword MajorTopicYN="Y">risperidone</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2023</Year>
          <Month>2</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35137229</ArticleId>
        <ArticleId IdType="pmc">PMC9077426</ArticleId>
        <ArticleId IdType="doi">10.1093/schbul/sbac001</ArticleId>
        <ArticleId IdType="pii">6524050</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>

Hjorthøj
 C, Stürup AE, McGrath J, Nordentoft M. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. The lancet Psychiatry 02/22 2017;4(4):295–301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28237639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Leucht
 S, Crippa A, Siafis S, Patel MX, Orsini N, Davis JM. Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia. Am J Psychiatry. 2020;177(4):342–353.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31838873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Reynolds
 GP, Dalton CF, Watrimez W, Jackson J, Harte MK. Adjunctive lurasidone suppresses food intake and weight gain associated with olanzapine administration in rats. Clin Psychopharmacol Neurosci. 2019;17(2):314–317.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6478088</ArticleId>
            <ArticleId IdType="pubmed">30905132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Kirk
 SL, Neill JC, Jones DN, Reynolds GP. Ziprasidone suppresses olanzapine-induced increases in ingestive behaviour in the rat. Eur J Pharmacol. 2004;505(1-3):253–254.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15556160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Crippa
 A, Orsini N. Dose-response meta-analysis of differences in means. BMC Med Res Methodol. 2016;16:91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4971698</ArticleId>
            <ArticleId IdType="pubmed">27485429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Stefan
 L, Hamza T, Siafis S, Wu H, Schneider-Thoma J, Davis J. Dose-response meta-analysis of the efficacy and side-effects of antipsychotic drugs in schizophrenia. PROSPERO 2020:CRD42020181467. https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020181467</Citation>
        </Reference>
        <Reference>
          <Citation>

Huhn
 M, Nikolakopoulou A, Schneider-Thoma J, et al. 
 Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939–951.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6891890</ArticleId>
            <ArticleId IdType="pubmed">31303314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Zhu
 Y, Li C, Huhn M, et al. 
 How well do patients with a first episode of schizophrenia respond to antipsychotics: a systematic review and meta-analysis. Eur Neuropsychopharmacol. 2017;27(9):835–844.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28669774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Samara
 MT, Dold M, Gianatsi M, et al. 
 Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. JAMA Psychiatry. 2016;73(3):199–210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26842482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Krause
 M, Zhu Y, Huhn M, et al. 
 Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2018;268(7):625–639.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29368205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Leucht
 S, Samara M, Heres S, Patel MX, Woods SW, Davis JM. Dose equivalents for second-generation antipsychotics: the minimum effective dose method. Schizophr Bull. 2014;40(2):314–326.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3932104</ArticleId>
            <ArticleId IdType="pubmed">24493852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Rothe
 PH, Heres S, Leucht S. Dose equivalents for second generation long-acting injectable antipsychotics: the minimum effective dose method. Schizophr Res. 2018;193:23–28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28735640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Leucht
 S, Samara M, Heres S, Davis JM. Dose equivalents for antipsychotic drugs: the DDD Method. Schizophr Bull. 2016;42Suppl 1:S90–S94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4960429</ArticleId>
            <ArticleId IdType="pubmed">27460622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Leucht
 S, Samara M, Heres S, et al. 
 Dose equivalents for second-generation antipsychotic drugs: the classical mean dose method. Schizophrenia bulletin 2015.</Citation>
        </Reference>
        <Reference>
          <Citation>

Leucht
 S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry. 2009;14(4):429–447.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18180760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Leucht
 S, Komossa K, Rummel-Kluge C, et al. 
 A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166(2):152–163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19015230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Leucht
 S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19058842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Leucht
 S, Cipriani A, Spineli L, et al. 
 Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–962.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23810019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Belgamwar
 RB, El-Sayeh HG. Aripiprazole versus placebo for schizophrenia. Cochrane Database Syst Rev. 2011;(8):CD006622.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21833956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Rattehalli
 RD, Zhao S, Li BG, Jayaram MB, Xia J, Sampson S. Risperidone versus placebo for schizophrenia. Cochrane Database Syst. Rev 2016;12:CD006918.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6463908</ArticleId>
            <ArticleId IdType="pubmed">27977041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Joy
 CB, Adams CE, Lawrie SM. Haloperidol versus placebo for schizophrenia. Cochrane Database Syst Rev. 2006;(
4):CD003082.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17054159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Li
 C, Xia J, Wang J. Risperidone dose for schizophrenia. Cochrane Database Syst Rev. 2009;(4):CD007474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19821422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Waraich
 P, Adams C, Hammill K, Marti J, Roque M. Haloperidol dose for the acutely ill phase of schizophrenia. Cochrane Database SystRev 2002;2:CD001951.</Citation>
        </Reference>
        <Reference>
          <Citation>

Tong
 Z, Li F, Ogawa Y, Watanabe N, Furukawa TA. Quality of randomized controlled trials of new generation antidepressants and antipsychotics identified in the China National Knowledge Infrastructure (CNKI): a literature and telephone interview study. BMC Med Res Methodol. 2018;18(1):96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6154421</ArticleId>
            <ArticleId IdType="pubmed">30249204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Higgins
 JPT, Green S.
 Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Chichester, UK: Wiley and Sons; 2011.</Citation>
        </Reference>
        <Reference>
          <Citation>

Crippa
 A, Discacciati A, Bottai M, Spiegelman D, Orsini N. One-stage dose-response meta-analysis for aggregated data. Stat Methods Med Res. 2019;28(5):1579–1596.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29742975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Crippa
 A, Orisini N. Multivariate dose-response meta-analysis: the dosresmeta R package. J Stat Softw. 2016;72(1):1–15.</Citation>
        </Reference>
        <Reference>
          <Citation>

Samara
 MT, Spineli LM, Furukawa TA, et al. 
 Imputation of response rates from means and standard deviations in schizophrenia. Schizophr Res. 2013;151(1-3):209–214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24262679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Kishimoto
 T, Hagi K, Kurokawa S, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry. 2021;8(5):387–404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33862018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Meltzer
 HY, Lindenmayer JP, Kwentus J, Share DB, Johnson R, Jayathilake K. A six month randomized controlled trial of long acting injectable risperidone 50 and 100mg in treatment resistant schizophrenia. Schizophr Res. 2014;154(1-3):14–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24630262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Meltzer
 HY, Share DB, Jayathilake K, Salomon RM, Lee MA. Lurasidone improves psychopathology and cognition in treatment-resistant schizophrenia. J Clin Psychopharmacol. 2020;40(3):240–249.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7188269</ArticleId>
            <ArticleId IdType="pubmed">32332459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Zimbroff
 DL, Kane JM, Tamminga CA, et al. 
 Controlled, dose response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997;154(6):782–791.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9167505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

van Kammen
 DP, McEvoy JP, Targum SD, Kardatzke D, Sebree TB. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology (Berl). 1996;124(1-2):168–175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8935813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Zborowski
 J, Schmitz P, Staser J, et al. 
 Efficacy and safety of sertindole in a trial of schizophrenic patients. BiolPsychiatry 1995;37:661–662.</Citation>
        </Reference>
        <Reference>
          <Citation>

Balduzzi
 S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22(4):153–160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31563865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
R Core Team. R: A language and Environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2019. https://www.R-project.org/.</Citation>
        </Reference>
        <Reference>
          <Citation>

Puech
 A, Fleurot O, Rein W. Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. Acta Psychiatr Scand 1998;98(1):65–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9696517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Cantillon
 M. Efficacy and safety of novel dopamine serotonin stabilizer rp 5063 in acute schizophrenia and schizoaffective disorder. Schizophr Res 2014;153:S22.</Citation>
        </Reference>
        <Reference>
          <Citation>

Kane
 JM, Carson WH, Saha AR, et al. 
 Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002;63(9):763–771.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12363115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

McEvoy
 JP, Daniel DG, Carson WH Jr, McQuade RD, Marcus RN. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. J Psychiatr Res. 2007;41(11):895–905.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17631314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Correll
 CU, Skuban A, Hobart M, et al. 
 Efficacy of brexpiprazole in patients with acute schizophrenia: review of three randomized, double-blind, placebo-controlled studies. Schizophr Res. 2016;174(1-3):82–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27157799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Durgam
 S, Cutler AJ, Lu K, et al. 
 Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. J Clin Psychiatry. 2015;76(12):e1574–e1582.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26717533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Potkin
 SG, Saha AR, Kujawa MJ, et al. 
 Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003;60(7):681–690.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12860772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Petrie
 JL, Saha AR, McEvoy JP. Aripiprazole, a new typical antipsychotic: Phase 2 clinical trial result. European Neuropsychopharmacology. 1997;1002(7):S227.</Citation>
        </Reference>
        <Reference>
          <Citation>

Kane
 JM, Peters-Strickland T, Baker RA, et al. 
 Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014;75(11):1254–1260.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25188501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Meltzer
 HY, Risinger R, Nasrallah HA, et al. 
 A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. J Clin Psychiatry. 2015;76(8):1085–1090.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26114240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Kane
 JM, Cohen M, Zhao J, Alphs L, Panagides J. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol. 2010;30(2):106–115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20520283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Landbloom
 R, Mackle M, Wu X, et al. 
 Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control. CNS Spectr. 2017;22(4):333–341.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27821210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Kinoshita
 T, Bai YM, Kim JH, Miyake M, Oshima N. Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study. Psychopharmacology (Berl). 2016;233(14):2663–2674.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4917598</ArticleId>
            <ArticleId IdType="pubmed">27271087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Potkin
 SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry. 2007;68(10):1492–1500.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17960962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
NCT02876900. Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia. https://ClinicalTrials.gov/show/NCT02876900. Accessed December 20, 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>

Correll
 CU, Skuban A, Ouyang J, et al. 
 Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2015;172(9):870–880.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25882325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Ishigooka
 J, Iwashita S, Tadori Y. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: a 6-week, randomized, double-blind, placebo-controlled study. Psychiatry Clin Neurosci. 2018;72(9):692–700.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29774628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Kane
 JM, Skuban A, Ouyang J, et al. 
 A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res. 2015;164(1-3):127–135.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25682550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
NCT00905307. Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia. https://ClinicalTrials.gov/show/NCT00905307. Accessed December 20, 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>

Durgam
 S, Starace A, Li D, et al. 
 An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res. 2014;152(2-3):450–457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24412468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Durgam
 S, Litman RE, Papadakis K, Li D, Németh G, Laszlovszky I. Cariprazine in the treatment of schizophrenia: a proof-of-concept trial. Int Clin Psychopharmacol. 2016;31(2):61–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4736298</ArticleId>
            <ArticleId IdType="pubmed">26655732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Kane
 JM, Zukin S, Wang Y, et al. 
 Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial. J Clin Psychopharmacol. 2015;35(4):367–373.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26075487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Simpson
 GM, Josiassen RC, Stanilla JK, et al. 
 Double-blind study of clozapine dose response in chronic schizophrenia. Am J Psychiatry. 1999;156(11):1744–1750.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10553738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Arvanitis
 LA, Miller BG, group Sts . Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233–246.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9270900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Beasley
 CM
 Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996;14(2):111–123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8822534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Chouinard
 G, Jones B, Remington G. Canadian placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7683702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Marder
 SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151(6):825–835.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7514366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Meltzer
 HY, Arvanitis L, Bauer D, Rein W; Meta-Trial Study Group . Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry. 2004;161(6):975–984.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15169685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Potkin
 SG, Kimura T, Guarino J. A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia. Ther Adv Psychopharmacol. 2015;5(6):322–331.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4722503</ArticleId>
            <ArticleId IdType="pubmed">26834965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Potkin
 SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol. 2008;28(2 Suppl 1):S4–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18334911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Cutler
 AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol. 2008;28(2 Suppl 1):S20–S28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18334909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Correll
 CU, Davis RE, Weingart M, et al. 
 Efficacy and safety of lumateperone for treatment of schizophrenia: a randomized clinical trial. JAMA Psychiatry 2020;77(4):349–358.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6990963</ArticleId>
            <ArticleId IdType="pubmed">31913424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Lieberman
 JA, Davis RE, Correll CU, et al. 
 ITI-007 for the treatment of schizophrenia: a 4-week randomized, double-blind, controlled trial. Biol Psychiatry. 2016;79(12):952–961.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26444072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
NCT02469155. A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment. https://ClinicalTrials.gov/show/NCT02469155. Accessed December 20, 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>

Loebel
 A, Silva R, Goldman R, et al. 
 Lurasidone dose escalation in early nonresponding patients with schizophrenia: a randomized, placebo-controlled study. J Clin Psychiatry 2016;77(12):0–.</Citation>
        </Reference>
        <Reference>
          <Citation>

Higuchi
 T, Ishigooka J, Iyo M, et al. 
 Lurasidone in the treatment of schizophrenia: results of a double-blind, placebo-controlled trial in Asian patients. Asia‐Pacific Psychiatry 2019;11(2):e12352.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30950208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Ogasa
 M, Kimura T, Nakamura M, Guarino J. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacology (Berl). 2013;225(3):519–530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3546299</ArticleId>
            <ArticleId IdType="pubmed">22903391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Nakamura
 M, Ogasa M, Guarino J, et al. 
 Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(6):829–836.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19497249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Nasrallah
 HA, Silva R, Phillips D, et al. 
 Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. J Psychiatr Res. 2013;47(5):670–677.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23421963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Meltzer
 HY, Cucchiaro J, Silva R, et al. 
 Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry. 2011;168(9):957–967.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21676992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Loebel
 A, Cucchiaro J, Sarma K, et al. 
 Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res. 2013;145(1-3):101–109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23415311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Iyo
 M, Ishigooka J, Nakamura M, et al. 
 Efficacy and safety of lurasidone in acutely psychotic patients with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled study. Psychiatry Clin Neurosci 2021;75:227–235.</Citation>
        </Reference>
        <Reference>
          <Citation>

Beasley
 CM
 Jr, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl). 1996;124(1-2):159–167.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8935812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Beasley
 CM
 Jr, Hamilton SH, Crawford AM, et al. 
 Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol. 1997;7(2):125–137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9169300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Bugarski-Kirola
 D, Wang A, Abi-Saab D, Blättler T. A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia–results from the CandleLyte study. Eur Neuropsychopharmacol. 2014;24(7):1024–1036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24735806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Davidson
 M, Emsley R, Kramer M, et al. 
 Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res. 2007;93(1-3):117–130.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17466492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Hirayasu
 Y, Tomioka M, Iizumi M, Kikuchi H. A double-blind, placebo-controlled, comparative study of paliperidone extended release (ER) tablets in patients with schizophrenia. Jpn J Clin Psychopharmacol 2010;13(11):2077–2103.</Citation>
        </Reference>
        <Reference>
          <Citation>
Kane JCFKMFLG-MCLPEM. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Roelofs, trans. Schizophr Res. 2007;90:147–161.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17092691</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Kinon
 BJ, Volavka J, Stauffer V, et al. 
 Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J Clin Psychopharmacol. 2008;28(4):392–400.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18626265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Kinon
 BJ, Zhang L, Millen BA, et al. ; HBBI Study Group . A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol. 2011;31(3):349–355.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21508856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Litman
 RE, Smith MA, Desai DG, Simpson T, Sweitzer D, Kanes SJ. The selective neurokinin 3 antagonist AZD2624 does not improve symptoms or cognition in schizophrenia: a proof-of-principle study. J Clin Psychopharmacol. 2014;34(2):199–204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24525659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Marder
 SR, Kramer M, Ford L, et al. 
 Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry. 2007;62(12):1363–1370.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17601495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Patil
 ST, Zhang L, Martenyi F, et al. 
 Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med. 2007;13(9):1102–1107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17767166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Shen
 JH, Zhao Y, Rosenzweig-Lipson S, et al. 
 A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia. J Psychiatr Res. 2014;53:14–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24613032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Lauriello
 J, Lambert T, Andersen S, Lin D, Taylor CC, McDonnell D. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry. 2008;69(5):790–799.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18452346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Canuso
 CM, Lindenmayer JP, Kosik-Gonzalez C, et al. 
 A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder. J Clin Psychiatry. 2010;71(5):587–598.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20492853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Coppola
 D, Melkote R, Lannie C, et al. 
 Efficacy and safety of paliperidone extended release 1.5 mg/day-a double-blind, placebo- and active-controlled, study in the treatment of patients with schizophrenia. Psychopharmacol Bull. 2011;44(2):54–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5044480</ArticleId>
            <ArticleId IdType="pubmed">27738355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Gopal
 S, Hough DW, Xu H, et al. 
 Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol. 2010;25(5):247–256.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20389255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Kramer
 M, Litman R, Hough D, et al. 
 Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol. 2010;13(5):635–647.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19941696</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Nasrallah
 HA, Gopal S, Gassmann-Mayer C, et al. 
 A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology. 2010;35(10):2072–2082.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3055301</ArticleId>
            <ArticleId IdType="pubmed">20555312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Pandina
 GJ, Lindenmayer JP, Lull J, et al. 
 A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol. 2010;30(3):235–244.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20473057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Cutler
 AJ, Tran-Johnson T, Kalali A, Aström M, Brecher M, Meulien D. A failed 6-week,randomized, double-blind, placebo-controlled study of once-daily extended release quetiapine fumarate in patients with acute schizophrenia: lessons learned. Psychopharmacol Bull. 2010;43(4):37–69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21240151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Honer
 WG, MacEwan GW, Gendron A, et al. ; STACK Study Group . A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2012;73(1):13–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21733490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Kahn
 RS, Schulz SC, Palazov VD, et al. ; Study 132 Investigators . Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(6):832–842.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17592906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Lindenmayer
 JP, Brown D, Liu S, Brecher M, Meulien D. The efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled study. Psychopharmacol Bull. 2008;41(3):11–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18779774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Lindenmayer
 JP, Citrome L, Khan A, Kaushik S, Kaushik S. A randomized, double-blind, parallel-group, fixed-dose, clinical trial of quetiapine at 600 versus 1200 mg/d for patients with treatment-resistant schizophrenia or schizoaffective disorder. J Clin Psychopharmacol. 2011;31(2):160–168.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21346616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Casey
 DE, Sands EE, Heisterberg J, Yang HM. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology (Berl). 2008;200(3):317–331.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18597078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Litman
 RE, Smith MA, Doherty JJ, et al. 
 AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: a proof of principle study. Schizophr Res. 2016;172(1-3):152–157.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26922656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Meltzer
 H, Barbato L, Heisterberg J, Yeung P, Shapira N. A randomized, double-blind, placebo-controlled efficacy and safety study of bifeprunox as treatment for patients with acutely exacerbated schizophrenia. Schizophrenia Bulletin 2007;33(2):446–446.</Citation>
        </Reference>
        <Reference>
          <Citation>

Meltzer
 HY, Elkis H, Vanover K, et al. 
 Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day. Schizophr Res. 2012;141(2-3):144–152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22954754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Peuskens
 J, Group. RS . Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995;166(6):712–726.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7545060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Potkin
 SG, Gutierrez R. Safety and efficacy of once-daily risperidone in the treatment of schizophrenia. In 150th Annual Meeting of the American Psychiatric Association. San Diego, CA; 1997.</Citation>
        </Reference>
        <Reference>
          <Citation>

Nasser
 AF, Henderson DC, Fava M, et al. 
 Efficacy, safety, and tolerability of RBP-7000 once-monthly risperidone for the treatment of acute schizophrenia: an 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study. J Clin Psychopharmacol. 2016;36(2):130–140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26862829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Kane
 JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003;160(6):1125–1132.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12777271</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Correll
 CU, Litman RE, Filts Y, et al. 
 Efficacy and safety of once-monthly Risperidone ISM® in schizophrenic patients with an acute exacerbation. NPJ Schizophr. 2020;6(1):37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7688968</ArticleId>
            <ArticleId IdType="pubmed">33239746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Daniel
 DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology. 1999;20(5):491–505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10192829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Goff
 DC, Posever T, Herz L, et al. 
 An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol. 1998;18(4):296–304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9690695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Goff
 DC, McEvoy JP, Citrome L, et al. 
 High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study. J Clin Psychopharmacol. 2013;33(4):485–490.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23775057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Keck
 P
 Jr, Buffenstein A, Ferguson J, et al. 
 Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl). 1998;140(2):173–184.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9860108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
128-301 S. Study report of study 128-301. Pfizer, data on file; 1997.</Citation>
        </Reference>
        <Reference>
          <Citation>
104 S. Center for drug evaluation and research approval package for application number 20-825. Med Rev. http://www.fda.gov; 1998.</Citation>
        </Reference>
        <Reference>
          <Citation>
115 2000 S. Center for drug evaluation and research approval package for application number 20-825. Med Rev. http://www.fda.gov. 2000.</Citation>
        </Reference>
        <Reference>
          <Citation>

Uzun
 S, Folnegović-Šmalc V, Mimica N, et al. 
 Ziprasidone clinical trials conducted in Croatia. Paper presented at: Abstracts for the XIth Biennial Winter Workshop on Schizophrenia Research; u. Schizophr. Res. 2002;3(S1):B84.</Citation>
        </Reference>
        <Reference>
          <Citation>

Cooper
 S, Tweed J, Raniwalla J, Butler A, Welch C. A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia. Acta Psychiatrica Scandinavica 2000;101(3):218–225.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10721870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Lecrubier
 Y, Quintin P, Bouhassira M, Perrin E, Lancrenon S. The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial. Kurland, trans. Acta Psychiatrica Scandinavica. 2006:114;319–327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17022791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Danion
 JM, Rein W, Fleurot O, Group AS. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Danion, trans. Am J Psychiatry. 1999;156:610–616.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10200742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Loo
 H, Poirier-Littre MF, Theron M, Rein W, Fleurot O. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry. 1997;170:18–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9068769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Pillinger
 T, McCutcheon RA, Vano L, et al. 
 Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7(1):64–77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7029416</ArticleId>
            <ArticleId IdType="pubmed">31860457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Siafis
 S, Davis JM, Leucht S.
 Antipsychotic drugs: from “major tranquilizers” to Neuroscience-based-Nomenclature. Psychol Med. 2021;51(3):522–524.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31910928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Kaar
 SJ, Natesan S, McCutcheon R, Howes OD. Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. Neuropharmacology. 2020;172:107704.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31299229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

De Hert
 M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011;8(2):114–126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22009159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Simon
 V, van Winkel R, De Hert M. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry. 2009;70(7):1041–1050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19653979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Siafis
 S, Tzachanis D, Samara M, Papazisis G. Antipsychotic drugs: from receptor-binding profiles to metabolic side effects. Curr Neuropharmacol. 2018;16(8):1210–1223.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6187748</ArticleId>
            <ArticleId IdType="pubmed">28676017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Dayabandara
 M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat. 2017;13:2231–2241.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5574691</ArticleId>
            <ArticleId IdType="pubmed">28883731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Alvarez-Jiménez
 M, González-Blanch C, Crespo-Facorro B, et al. 
 Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs. 2008;22(7):547–562.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18547125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Gentile
 S. Long-term treatment with atypical antipsychotics and the risk of weight gain: a literature analysis. Drug Saf. 2006;29(4):303–319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16569080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Bazo-Alvarez
 JC, Morris TP, Carpenter JR, Hayes JF, Petersen I. Effects of long-term antipsychotics treatment on body weight: a population-based cohort study. J Psychopharmacol. 2020;34(1):79–85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6947810</ArticleId>
            <ArticleId IdType="pubmed">31724905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Veerman
 SRT, Schulte PFJ, de Haan L. Treatment for negative symptoms in schizophrenia: a comprehensive review. Drugs. 2017;77(13):1423–1459.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28776162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Bak
 M, Fransen A, Janssen J, van Os J, Drukker M. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One. 2014;9(4):e94112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3998960</ArticleId>
            <ArticleId IdType="pubmed">24763306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Hamza
 T, Furukawa TA, Orsini N, Cipriani A, Iglesias C, Salanti G. A dose-effect network meta-analysis model: an application in antidepressants. arXiv preprint arXiv 210405414 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>

Mawdsley
 D, Bennetts M, Dias S, Boucher M, Welton NJ. Model-based network meta-analysis: a framework for evidence synthesis of clinical trial data. CPT Pharmacometrics Syst Pharmacol. 2016;5(8):393–401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4999602</ArticleId>
            <ArticleId IdType="pubmed">27479782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Musil
 R, Obermeier M, Russ P, Hamerle M. Weight gain and antipsychotics: a drug safety review. Expert Opin Drug Saf. 2015;14(1):73–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25400109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Bazo-Alvarez
 JC, Morris TP, Carpenter JR, Hayes JF, Petersen I. Effects of long-term antipsychotics treatment on body weight: a population-based cohort study. J Psychopharmacol. 2020;34(1):79–85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6947810</ArticleId>
            <ArticleId IdType="pubmed">31724905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Kapfhammer
 A, Schestag K, Leucht S. Systematic review and network meta-analysis about metabolic side effects of antipsychotic drugs in individuals with schizophrenia during medium- to long-term treatment: Methods and preliminary results. Poster presented at: 8th European Conference on Schizophrenia Research. 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>

Maayan
 L, Correll CU. Management of antipsychotic-related weight gain. Expert Rev Neurother. 2010;10(7):1175–1200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3501406</ArticleId>
            <ArticleId IdType="pubmed">20586697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Correll
 CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med. 2011;17(2):97–107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3053585</ArticleId>
            <ArticleId IdType="pubmed">21185230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Nielsen
 MØ, Rostrup E, Wulff S, Glenthøj B, Ebdrup BH. Striatal reward activity and antipsychotic-associated weight change in patients with schizophrenia undergoing initial treatment. JAMA Psychiatry. 2016;73(2):121–128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26747088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Rabinowitz
 J, Bromet EJ, Davidson M. Are patients enrolled in first episode psychosis drug trials representative of patients treated in routine clinical practice? Schizophr Res. 2003;61(2-3):149–155.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12729866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Taipale
 H, Schneider-Thoma J, Pinzón-Espinosa J, et al. 
 Real-world representation and outcomes of individuals with schizophrenia not eligible for RCTs. JAMA Psychiatry (accepted for publication) 2021.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
